Dwu-, trzy- i czterolekowe schematy w leczeniu pierwszoliniowym szpiczaka plazmocytowego z uwzględnieniem efektów terapii z zastosowaniem bortezomibu

The last ASH conference 2012 provided further reports confirming the efficacy of bortezomib in the treatment of newly diagnosed myeloma, both in younger patients eligible for stem cell transplantation, and elderly who are not candidates for this procedure. Moreover, a few reports suggested that neurotoxicity associated with bortezomib might be significantly reduced with subcutaneous administration.